Sunder Biomedical Tech Valuation

Is 4115 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 4115 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 4115's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 4115's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 4115?

Key metric: As 4115 is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 4115. This is calculated by dividing 4115's market cap by their current book value.
What is 4115's PB Ratio?
PB Ratio	n/a
Book	NT$0
Market Cap	NT$627.00m

4115 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	n/a
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does 4115's PB Ratio compare to its peers?

The above table shows the PB ratio for 4115 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	1.4x
4183 EPS Bio Technology	1.8x	n/a	NT$549.8m
1813 Polylite Taiwan	1.2x	n/a	NT$916.4m
3373 Radiant Innovation	1.1x	n/a	NT$952.4m
6543 Perfect Medical Industry	1.6x	n/a	NT$1.3b
4115 Sunder Biomedical Tech	n/a	n/a	NT$627.0m

Price-To-Book vs Peers: Insufficient data to calculate 4115's Price-To-Book Ratio vs. peers for valuation analysis.

Price to Book Ratio vs Industry

How does 4115's PB Ratio compare vs other companies in the TW Medical Equipment Industry?

0 Companies	Price / Book	Estimated Growth	Market Cap

0 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Book vs Industry: Insufficient data to calculate 4115's Price-To-Book Ratio vs. industry for valuation analysis.

Price to Book Ratio vs Fair Ratio

What is 4115's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

4115 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	n/a
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 4115's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Concord Medical

NT$883.3m

Provides hospital management support services in Taiwan, Myanmar, and China.

6518

NT$26.50

0.4%

14.2%

Ma Kuang Healthcare Holding

NT$1.3b

An investment holding company, provides medical services in Taiwan and internationally.

4139

NT$30.60

2.0%

-18.2%

Hi-Clearance

NT$6.1b

Supplies medical devices for the renal, cardiac, radiation, dental, oral surgery, and metabolism markets in Taiwan.

1788

NT$138.00

-0.7%

1.1%